Popular Education
Talk Infusion: Mid-2024 Regulatory and Legislative Updates
Catch up with the latest billing policy updates as well as regulatory and legislative action affecting home and alternate site infusion providers.
Talk Infusion: Preparing for 2024: Regulatory & Reimbursement Updates
Catch the latest regulatory updates impacting the home and alternate site infusion industry as we gear up for 2024.
Amikacin Safety and Efficacy in Multi-Drug Resistant Tuberculosis
Multi-drug resistant tuberculosis (MDR-TB) has become a leading world health crisis. MDR-TB is defined as resistance to the potent cornerstone TB drugs, isoniazid and rifampin. Approximately, 3% of newly infected cases and 20% of pre-existing TB cases are diagnosed with MDR-TB.
